- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 02.12. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 01.11. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.10. | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 448 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| 23.10. | Lixte Biotechnology granted extension to meet Nasdaq listing rules | 3 | Investing.com | ||
| 23.10. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10. | Lixte Biotechnology files to sell units, no amount given | 14 | Seeking Alpha | ||
| 23.10. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.09. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Receives U.S. Patent Issue Notification for Immune Oncology | 121 | GlobeNewswire (Europe) | Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW)... ► Artikel lesen | |
| 26.08. | Lixte Biotechnology Holdings, Inc.: First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company | 153 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new... ► Artikel lesen | |
| 23.08. | Lixte Biotechnology faces Nasdaq delisting over equity shortfall | 2 | Investing.com | ||
| 19.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Recent Activities and Developments | 277 | GlobeNewswire (Europe) | -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical... ► Artikel lesen | |
| 15.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings to Present at Two Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 15.08. | Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event | 261 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing... ► Artikel lesen | |
| 08.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.06. | Lixte, Roche, Netherlands Cancer Institute Collaborate For Colon Cancer Trial; Stock Up | 485 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - Lixte Biotechnology Holdings, Inc. (LIXT), Friday announced a partnership with Swiss healthcare company Roche Holding AG (RHHBY) and the Netherlands Cancer Institute... ► Artikel lesen | |
| 14.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial | 261 | GlobeNewswire (Europe) | Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,780 | +1,71 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OCUGEN | 0,718 | -2,45 % | Ocugen: Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Vereinbarung mit Quest Diagnostics über die Bereitstellung von Labor-Services im Rahmen der klinischen Studie für den Darmkrebsfrüherkennungstest bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed gibt Vereinbarung mit Quest Diagnostics über die Bereitstellung von Labor-Services im Rahmen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 40,570 | +0,07 % | AKTIEN IM FOKUS: Novo Nordisk sacken nach Daten ab - Gerresheimer schwach | KOPENHAGEN/FRANKFURT/NEW YORK (dpa-AFX) - Enttäuschende Studienergebnisse haben dem dänischen Pharmakonzern Novo Nordisk am Freitag den höchsten Kursverlust in seiner Geschichte eingebrockt. Die Papiere... ► Artikel lesen | |
| IMMUNITYBIO | 2,488 | -1,15 % | ImmunityBio Reports Third-Quarter 2024 Financial Results | CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024.
ANKTIVA® received a J-code (HCPCS... ► Artikel lesen | |
| MARINOMED BIOTECH | 14,300 | -3,70 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei Agrob, Haier, Marinomed, Multitude, Weng Fine Art, Wolford | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| ORAGENICS | 0,366 | -1,37 % | ORAGENICS INC - S-1, General form for registration of securities | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| FIBROGEN | 0,340 | -12,00 % | FibroGen Aktie: Vorzeigemodell für Erfolg! | Die FibroGen Aktie verzeichnete am 21. Dezember 2024 einen beachtlichen Anstieg von 5,13 Prozent und schloss bei 0,41 EUR. Der Biotechnologiekonzern, der sich auf die Entwicklung von Therapeutika für... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,003 | -60,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections | TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| BIOLINERX | 0,204 | +6,25 % | BioLineRx-Aktie erreicht 52-Wochen-Tief bei 0,21 US-Dollar | ||
| CAPRICOR | 12,660 | +0,80 % | Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress | -Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle... ► Artikel lesen | |
| RADIUS HEALTH | - | - | Radius Health: Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia | BOSTON, MA / ACCESSWIRE / December 9, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused... ► Artikel lesen | |
| MARKER THERAPEUTICS | 3,440 | -11,79 % | Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma | APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well... ► Artikel lesen | |
| SCHOLAR ROCK | 42,400 | -1,40 % | Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,060 (+3,12 %) liegt der Kurs bei 1,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
